From: Benefits, challenges and obstacles of adaptive clinical trial designs
Randomization Ratio | Failure Rate | Power | |||
---|---|---|---|---|---|
 | Placebo | Test | 80% | 85% | 90% |
1:1 | 60% | 30% | 80 (40) | 90 (45) | 106 (53) |
 | 55% | 27% | 90 (45) | 102 (51) | 120 (60) |
 | 50% | 25% | 110 (55) | 126 (63) | 148 (74) |
 | 45% | 22% | 126 (63) | 144 (72) | 168 (84) |
 | 40% | 20% | 158 (79) | 180 (90) | 212 (106) |
2:1 | 60% | 30% | 93 (62) | 105 (70) | 123 (82) |
 | 55% | 27% | 105 (70) | 120 (80) | 141 (94) |
 | 50% | 25% | 132 (88) | 150 (100) | 174 (116) |
 | 45% | 22% | 150 (100) | 171 (114) | 201 (134) |
 | 40% | 20% | 189 (126) | 216 (144) | 255 (170) |